Early apoptotic cells for use in treating sepsis
AssigneeEnlivex Therapeutics R&D Ltd
InventorsShai Novik, Dror Mevorach
Life of this patent
Estimating the term…
Abstract
Compositions disclosed herein, and methods of use thereof included those for treating or preventing sepsis in a subject in need, including methods of extending of the survival of a subject suffering from sepsis, and reduction of organ dysfunction or failure due to sepsis. Methods of treating or preventing sepsis in a subject in need includes administering compositions comprising early apoptotic cells or early apoptotic cell supernatants. Compositions and methods of use thereof may reduce the negative proinflammatory effect accompanying sepsis. Further, anti-inflammatory cytokine release may be reduced. In certain instances, compositions may include additional agents.
Claims20
A method of treating, preventing, inhibiting, reducing the incidence of, ameliorating, or alleviating, sepsis-related organ dysfunction, or any combination thereof, in a subject in need, comprising the step of administering a composition comprising an early apoptotic cell population to said subject, wherein said early apoptotic cells comprise peripheral blood mononuclear cells, wherein at least two organ systems are dysfunctional in said subject, and wherein said administering treats, prevents, inhibits, reduces the incidence of, ameliorates, or alleviates sepsis-related organ dysfunction in said subject.
Dependencies are inferred from the claim text.